Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2530538rdf:typepubmed:Citationlld:pubmed
pubmed-article:2530538lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2530538lifeskim:mentionsumls-concept:C0085605lld:lifeskim
pubmed-article:2530538lifeskim:mentionsumls-concept:C0060400lld:lifeskim
pubmed-article:2530538lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2530538pubmed:issue32lld:pubmed
pubmed-article:2530538pubmed:dateCreated1989-12-21lld:pubmed
pubmed-article:2530538pubmed:abstractTextModifications of cefixime kinetics due to severe impairment of liver function were determined in 9 cirrhotic patients. Cefixime was administered as a single dose of 200 mg and levels were measured by HPLC. Maximum serum concentrations and area-under-the-curves of serum concentrations were not modified. The time for maximum serum concentration was delayed and the cefixime half-life in serum was prolonged, as a reflect of increased volume of distribution resulting from ascites and hypoalbuminemia. Renal clearance increased in these patients, possibly because of reduced extra-renal clearance. No metabolite was detected in serum or urine. Modifications of cefixime kinetics resulting from impaired hepatic function were modest and did not require specific dosage adjustment.lld:pubmed
pubmed-article:2530538pubmed:languagefrelld:pubmed
pubmed-article:2530538pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2530538pubmed:citationSubsetIMlld:pubmed
pubmed-article:2530538pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2530538pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2530538pubmed:statusMEDLINElld:pubmed
pubmed-article:2530538pubmed:monthOctlld:pubmed
pubmed-article:2530538pubmed:issn0755-4982lld:pubmed
pubmed-article:2530538pubmed:authorpubmed-author:SinglasEElld:pubmed
pubmed-article:2530538pubmed:authorpubmed-author:TaburetA MAMlld:pubmed
pubmed-article:2530538pubmed:authorpubmed-author:RocheGGlld:pubmed
pubmed-article:2530538pubmed:authorpubmed-author:LebrecDDlld:pubmed
pubmed-article:2530538pubmed:authorpubmed-author:GaudinCClld:pubmed
pubmed-article:2530538pubmed:authorpubmed-author:MontayGGlld:pubmed
pubmed-article:2530538pubmed:issnTypePrintlld:pubmed
pubmed-article:2530538pubmed:day11lld:pubmed
pubmed-article:2530538pubmed:volume18lld:pubmed
pubmed-article:2530538pubmed:ownerNLMlld:pubmed
pubmed-article:2530538pubmed:authorsCompleteYlld:pubmed
pubmed-article:2530538pubmed:pagination1587-8lld:pubmed
pubmed-article:2530538pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:meshHeadingpubmed-meshheading:2530538-...lld:pubmed
pubmed-article:2530538pubmed:year1989lld:pubmed
pubmed-article:2530538pubmed:articleTitle[Effect of hepatic failure upon the pharmacokinetics of cefixime].lld:pubmed
pubmed-article:2530538pubmed:affiliationPharmacie clinique, Hôpital Bicêtre.lld:pubmed
pubmed-article:2530538pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2530538pubmed:publicationTypeEnglish Abstractlld:pubmed